Coherent Capital

$8.65M Raised for Whole-Genome-Based Custom Probiotics

Sun Genomics Raises Series A for Personalized Probiotics

June 29, 2020

Sun Genomics, a San Diego DTC custom probiotics company, raised $8.65m in Series A funding. Led by Sunny Jain, CEO and founder, Sun Genomics provides personalized probiotic solutions based on whole-genome sequencing diagnostics.

The round was led by Pangaea Ventures with Danone Manifesto Ventures, SOSV, Human Longevity, and Nascita Ventures joining.

Sun Genomics will use the funding to grow sales in the custom probiotics market, scale their delivery operations across the United States and international markets, and accelerate the publication of studies in partnership with academic institutions.

Sun Genomics offers the flagship product Floré, a microbiome test and custom probiotics supplement that utilizes whole-genome sequencing and ensure that customers receive a completely personalized product that is based on their unique gut profiles.

Maggie SaundersJune 30, 2020

Securities are offered through Finalis Securities LLC Member FINRA/SIPC. Coherent Capital, LLC and Finalis Securities LLC are separate, unaffiliated entities. Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck

CoherentCapital.com is a website operated by Coherent Capital, LLC, a privately held California limited liability company. Coherent Capital, LLC provides financial and strategic advisory, consulting services, mergers and acquisitions services, fairness opinions, etc.].

Coherent Capital, LLC is not a registered broker-dealer, and Finalis Securities LLC and Coherent Capital, LLC are separate, unaffiliated entities.

Finalis does not make investment recommendations and no communication, through this website or in any other medium should be construed as a recommendation for any security. You can review the brokercheck for Finalis here. This website is intended solely for qualified investors. Investments in private offerings and startup investments in particular are speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in such offerings. Companies seeking startup investments tend to be in earlier stages of development and their business model, products and services may not yet be fully developed, operational or tested in the public marketplace. There is no guarantee that the stated valuation and other terms are accurate or in agreement with the market or industry valuations. Additionally, investors may receive restricted stock that may be subject to holding period requirements. Investments in early-stage private companies should only be part of your overall investment portfolio. Furthermore, the allocation to this asset sub-class may be best fulfilled through a balanced portfolio of different start-ups. Investments in startups are highly illiquid and those investors who cannot hold an investment for the long term (at least 5-7 years) should not invest. Business Continuity Plan for Finalis.